Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news


From To
SA can save billions with new HIV drug combination

The ADVANCE study will evaluate an HIV treatment regimen including two newer and cheaper drugs: dolutegravir (DTG) and tenofovir alafenamide (TAF).

17 January 2017
GlaxoSmithKline’s New Drug Challenges HIV Treatment Orthodoxy

GlaxoSmithKline PLC’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.

20 December 2016
Wall Street Journal
Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen

Janssen Sciences Ireland UC (Janssen) today announced that two Phase III studies to evaluate the safety and efficacy of switching virologically suppressed patients from a three or four drug (integrase inhibitor-, non-nucleoside reverse transcriptase inhibitor-, or boosted protease inhibitor-based) antiretroviral regimen to the two drug regimen of rilpivirine (Janssen) and dolutegravir (ViiV Healthcare) met the primary endpoint of non inferiority at week 48.

20 December 2016
Janssen press release
Charlie Sheen Achieves Undetectable Viral Load With Weekly Injectable HIV Treatment

Actor Charlie Sheen revealed this month that he has achieved an undetectable viral load by taking PRO 140, an injectable HIV drug that's currently being studied. Sheen started taking PRO 140 as a study participant in a phase-3 clinical trial that is looking into the drug's safety and effectiveness in humans.

08 December 2016
The Body
Top 10 HIV Clinical Developments of 2016

In typical years, a noteworthy development in the world of HIV would be the result of a landmark clinical trial or perhaps a gem of a lab study with a novel finding. But, 2016 was not typical. What made the most difference for people living with HIV and their health care providers this past year was less a paper published or presented than major shifts in our thinking about how best to prevent and manage HIV infection.

02 December 2016
The Body Pro
China to approve 1st long-acting injection to treat HIV/AIDS

China's national drug authority on Wednesday examined clinical research results on a domestically produced anti-HIV drug in its final phase prior to officially approving the drug. Once approved, the new-generation drug, named Albuvirtide for Injection, is expected to be the world's first long-acting injection for HIV treatment.

25 November 2016
Global Times
ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine

21 November 2016
ViiV press release
The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study

A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of subjects who were given an experimental

11 November 2016
Gus Cairns
‘Hard’ Brexit would delay access to new drugs, warns report

UK patients could see delays in access to new medicines if Brexit means leaving the single market, warns a new report published by think tank Public Policy Projects backed by health consultancy giant QuintilesIMS.

09 November 2016
Pharma Times
Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV

Ibalizumab, an experimental monoclonal antibody with a unique mechanism of action, demonstrated good safety and promising efficacy in a small phase 3 study of people with extensive

04 November 2016
Liz Highleyman
← First12345...94Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.